In respect to their cardiovascular effects among patients with T2DM, both GLP-1RAs and SGLT2is have been shown to reduce the risk of MACE (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke), with GLP-1RAs reducing the risk of non-fatal stroke to a greater extent [3, 6]
In insulin-resistant conditions, FOXC2 could inhibit the differentiation of adipose tissue and reduce the number of adipocytes present
Hims in March announced it would partner with Novo Nordisk for its branded drugs but would continue to sell compounded versions in special doses or formulations, as regulations allow
Here, well cover the main points to consider when going off GLP-1 therapy and what to expect
Reduced food and fluid intake on GLP-1 medications can cause electrolyte imbalances, manifesting as muscle cramps, headaches, or irregular heartbeat
Its also important to ensure that the temperature of the medication never exceeds 30C